OLMA earnings: next report 2026-08-10, real EPS beat/miss history, analyst consensus Buy, P/E -5.69. Updated 2026-07-23.
Olema Pharmaceuticals (OLMA) Research Hub
Olema Pharmaceuticals (OLMA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 10.22 USD (-1.35%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -5.69, market cap 0.99B. This hub links to the full technical, earnings and options research available for OLMA.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 10.22 USD (-1.35%) |
| 52-week range | 9.12 USD – 13.09 USD |
| Trend regime | Range |
| 14-day RSI | 33.3 (Bearish) |
| Trailing P/E | -5.69 |
| Market cap | 0.99B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for OLMA
Covered Call on OLMA: how it works, illustrative setup around the real 10.22 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on OLMA: how it works, illustrative setup around the real 10.22 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on OLMA: how it works, illustrative setup around the real 10.22 USD price, max profit/loss, breakeven and when to use it. Educational.
OLMA technical analysis: range, last 10.22 USD, RSI 33.3, 52w range 9.12 USD–13.09 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is OLMA in?
Olema Pharmaceuticals (OLMA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is OLMA in an uptrend or downtrend?
As of 2026-09-11, OLMA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is OLMA's trailing P/E ratio?
OLMA's trailing P/E is -5.69, with a market cap of 0.99B. See the earnings research page for full valuation detail.
When does OLMA next report earnings?
OLMA is next scheduled to report earnings on 2026-08-10, with a consensus EPS estimate of -0.53 USD.